Cargando…

ACE2 and COVID-19 and the resulting ARDS

This article reviews the correlation between ACE2 and COVID-19 and the resulting acute respiratory distress syndrome (ARDS). ACE2 is a crucial component of the renin-angiotensin system (RAS). The classical ACE-angiotensin Ⅱ (Ang II)-angiotensin type 1 receptor (AT1R) axis and the ACE2-Ang(1-7)-Mas c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaoqing, Li, Shuren, Niu, Shaoqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016912/ https://www.ncbi.nlm.nih.gov/pubmed/32522846 http://dx.doi.org/10.1136/postgradmedj-2020-137935

Ejemplares similares

Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19
por: Kuba, Keiji, et al.
Publicado: (2021)

Recombinant human ACE2: acing out angiotensin II in ARDS therapy
por: Zhang, Haibo, et al.
Publicado: (2017)

ACE-2 Expression and Methylation Pattern in Bronchoalveolar Lavage Fluid and Bloods of Iranian ARDS Covid-19 Patients
por: Najafipour, Reza, et al.
Publicado: (2022)

Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
por: Li, Zhongwen, et al.
Publicado: (2020)

ACE2, Metformin, and COVID-19
por: Malhotra, Atul, et al.
Publicado: (2020)

ACE and ACE2: insights from Drosophila and implications for COVID-19
por: Herrera, Paul, et al.
Publicado: (2021)

Acute respiratory failure in COVID-19: is it “typical” ARDS?
por: Li, Xu, et al.
Publicado: (2020)

CHANGES IN ARDS MANAGEMENT AS A RESULT OF THE COVID-19 PANDEMIC
por: MACHURICK, MAXWELL, et al.
Publicado: (2021)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients
por: Ceccato, Adrian, et al.
Publicado: (2022)

Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients
por: Tsolaki, Vasiliki, et al.
Publicado: (2022)

COVID-19 susceptibility: potential of ACE2 polymorphisms
por: Chaudhary, Mayank
Publicado: (2020)

ACE2, Circumventricular Organs and the Hypothalamus, and COVID-19
por: Ong, Wei-Yi, et al.
Publicado: (2022)

ARDS RELATED TO COVID-19
por: Sekhon, Jasmine, et al.
Publicado: (2020)

COVID-19 pneumonia: ARDS or not?
por: Gattinoni, Luciano, et al.
Publicado: (2020)

The incidence of ARDS, interim results of the East Anglian ARDS Registry
por: Dixon, JM, et al.
Publicado: (2000)

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
por: Ni, Wentao, et al.
Publicado: (2020)

Emerging pharmacological therapies for ARDS: COVID-19 and beyond
por: Horie, Shahd, et al.
Publicado: (2020)

Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis
por: Yu, Zhidan, et al.
Publicado: (2021)

COVID-19 ARDS: Points to Be Considered in Mechanical Ventilation and Weaning
por: Kondili, Eumorfia, et al.
Publicado: (2021)

COVID-19-Related ARDS: Key Mechanistic Features and Treatments
por: Selickman, John, et al.
Publicado: (2022)

Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS
por: Amini, Shahideh, et al.
Publicado: (2022)

Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
por: Xiao, Kun, et al.
Publicado: (2020)

Glycyrrhizin through liquorice intake modulates ACE2 and HMGB1 levels—A pilot study in healthy individuals with implications for COVID-19 and ARDS
por: Buder, Felix, et al.
Publicado: (2022)

ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis
por: Poznyak, Anastasia V., et al.
Publicado: (2021)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

Advances in Targeting ACE2 for Developing COVID-19 Therapeutics
por: Suvarnapathaki, Sanika, et al.
Publicado: (2022)

Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients
por: Akbari, Mohammadarian, et al.
Publicado: (2022)

The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients
por: Zamai, Loris
Publicado: (2020)

Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS
por: Jerath, Angela, et al.
Publicado: (2020)

ECMO for ARDS due to COVID-19
por: Ñamendys-Silva, Silvio A.
Publicado: (2020)

Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance
por: Scaramuzzo, Gaetano, et al.
Publicado: (2023)

Three-step research strategies for ARDS: new target molecules—ACE2, HMGB1, and HSP47
por: Iwasaka, Hideo
Publicado: (2007)

RESPIRATORY PHYSIOLOGICAL PARAMETERS AND OUTCOMES OF PATIENTS WITH COVID-19 ARDS AND NON-COVID-19 ARDS UNDERGOING ECMO
por: FEDERBUSH, M., et al.
Publicado: (2022)

ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
por: Dong, Mengzhen, et al.
Publicado: (2020)

The Protective Potential Role of ACE2 against COVID-19
por: Golab, Fereshteh, et al.
Publicado: (2023)

Corticosteroids in ARDS
por: Kuperminc, Emmanuelle, et al.
Publicado: (2023)

ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations
por: Snyder, Eric M, et al.
Publicado: (2020)

Gastrointestinal cancers, ACE-2/TMPRSS2 expression and susceptibility to COVID-19
por: Shafiee, Sepehr, et al.
Publicado: (2021)

Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants
por: Zhang, Lianghui, et al.
Publicado: (2021)

COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients
por: Sieńko, Jerzy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3sifjmuk6soa2ocq7bjvk2ad7